The Native Antigen Company introduces novel coronavirus antigens

As the reported death toll from the novel coronavirus passes 1,100 out of more than 44,000 known cases, The Native Antigen Company today announced the commercial introduction of its novel coronavirus antigens, derived from the emerging Wuhan strain.

These recombinant proteins offer scientists high-quality reagents to support ongoing infectious disease research, and the development of diagnostics and vaccines, says the Oxford, UK-based company.

The Native Antigen Company has developed rapid response manufacturing capabilities to produce reagents for emerging epidemic diseases according to the World Health Organization's R&D Blueprint, which urges the accelerated development of vaccines and the increased availability of accurate and reliable diagnostics for priority emerging infectious diseases.